On the fourth day of EASD 2026, seven key news items were observed from Boehringer Ingelheim, Lilly, BMS, Zealand Pharma, Novo, and Regeneron. Below, FENIX provides context and analysis for the announcements, including a pooled look at the off-protocol GLP-1RA use in BI’s pivotal SYNCHRONIZE studies.